Esmo 2021 First Line Nivolumab Cabozantinib Vs Sunitinib In Patients Nivolumab plus cabozantinib versus sunitinib in first line treatment for advanced renal cell carcinoma (checkmate 9er): long term follow up results from an open label, randomised, phase 3 trial. In this exploratory post hoc analysis of checkmate 9er, dr. porta and colleagues presented results assessing the efficacy of nivolumab cabozantinib versus sunitinib in patients with subgroups defined by baseline nephrectomy status after a minimum follow up of 16.0 months.
Esmo Virtual Congress 2020 Nivolumab Cabozantinib Vs Sunitinib In First line (1l) nivolumab cabozantinib (n c) significantly improved progression free survival (pfs), overall survival (os), and objective response rate (orr) vs sunitinib (s) in arcc pts in the phase iii checkmate 9er trial. In this first line phase 3 study, patients with advanced rcc in the intent to treat (itt) achieved superior os, pfs, and orr with nivolumab plus cabozantinib compared with sunitinib after a minimum follow up of 10.6 months, this efficacy was also maintained after 16.0 months of minimum follow up. In this study, we aimed to describe the patient reported outcome (pro) results from checkmate 9er. In the checkmate 9er trial, advanced renal cell carcinoma (arcc) patients received first line nivolumab cabozantinib or sunitinib. the effect of treatment was evaluated via patient reported outcomes (pros).
Esmo Virtual Congress 2020 Nivolumab Cabozantinib Vs Sunitinib In In this study, we aimed to describe the patient reported outcome (pro) results from checkmate 9er. In the checkmate 9er trial, advanced renal cell carcinoma (arcc) patients received first line nivolumab cabozantinib or sunitinib. the effect of treatment was evaluated via patient reported outcomes (pros). Score upgraded by 3 points (from 1 to 4) due to updated os data which was significant and mature. In this first line phase 3 study, patients with advanced rcc in the intent to treat (itt) achieved superior os, pfs, and orr with nivolumab plus cabozantinib compared with sunitinib. In this first line phase 3 study, patients with advanced rcc in the intent to treat (itt) achieved superior os, pfs, and orr with nivolumab plus cabozantinib compared with sunitinib after a minimum follow up of 10.6 months, this efficacy was also maintained after 16.0 months of minimum follow up. This study will confirm that the superior clinical efficacy of first line nivolumab plus cabozantinib vs sunitinib is matched with superior quality of life.
Comments are closed.